JOP20180088B1 - Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide - Google Patents

Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

Info

Publication number
JOP20180088B1
JOP20180088B1 JOP/2018/0088A JOP20180088A JOP20180088B1 JO P20180088 B1 JOP20180088 B1 JO P20180088B1 JO P20180088 A JOP20180088 A JO P20180088A JO P20180088 B1 JOP20180088 B1 JO P20180088B1
Authority
JO
Jordan
Prior art keywords
hydroxypyrrolidine
pyrazolo
difluorophenyl
pyrrolidin
pyrimidin
Prior art date
Application number
JOP/2018/0088A
Other languages
Arabic (ar)
Inventor
Mark Reynolds
Steven A Smith
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Priority to JOP/2018/0088A priority Critical patent/JOP20180088B1/en
Publication of JOP20180088A1 publication Critical patent/JOP20180088A1/en
Application granted granted Critical
Publication of JOP20180088B1 publication Critical patent/JOP20180088B1/en

Links

Abstract

A liquid formulation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutically acceptable salts thereof, or a combination thereof and the use of the liquid formulation in the treatment of pain, cancer, inflammation, and certain infectious diseases are disclosed.
JOP/2018/0088A 2018-10-02 2018-10-02 Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide JOP20180088B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JOP/2018/0088A JOP20180088B1 (en) 2018-10-02 2018-10-02 Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JOP/2018/0088A JOP20180088B1 (en) 2018-10-02 2018-10-02 Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

Publications (2)

Publication Number Publication Date
JOP20180088A1 JOP20180088A1 (en) 2020-04-02
JOP20180088B1 true JOP20180088B1 (en) 2023-09-17

Family

ID=75469090

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2018/0088A JOP20180088B1 (en) 2018-10-02 2018-10-02 Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

Country Status (1)

Country Link
JO (1) JOP20180088B1 (en)

Also Published As

Publication number Publication date
JOP20180088A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
PH12018502124A1 (en) Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
PH12021550809A1 (en) Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
PH12018502134A1 (en) Methods of treating pediatric cancers
ZA202303227B (en) Crystalline forms of a bruton's tyrosine kinase inhibitor
MX2021015408A (en) Pharmaceutical formulations of bruton's tyrosine kinase inhibtor.
MY161078A (en) Topical formulation for a jak inhibitor
EA200600820A1 (en) METHODS OF TREATMENT, MODIFICATION AND ELIMINATION OF PATIENTS USING 1-OXO-2- (2,6-DIOXOPYPERIDIN-3-IL) -4-METHYLISYNDOLINE
MX2021004546A (en) Implantable drug delivery compositions and methods of use thereof.
MX2014010590A (en) Combination therapy (vemrufenib and a mdm2 inhibitor) for the treatment proliferative disorders.
MX2017012430A (en) Solvated forms of a bruton's tyrosine kinase inhibitor.
MX2021010058A (en) Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders.
TW200503683A (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
JOP20180088B1 (en) Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
TWI799923B (en) Use of thioimidazolidinone drugs in the treatment of covid-19 disease
HUP0204208A2 (en) Antipruritic agents for external use
WO2007010337A8 (en) Use of phosphodiesterase type 5 inhibitors for the prevention and treatment of diseases or health disorders and dispensing system for said inhibitors
MX2022015438A (en) Dispersible tablet formulations comprising dolutegravir.
MX2019000159A (en) Substituted pyrrolo [2, 3-d] pyridazin-4-ones and pyrazolo [3, 4-d] pyridazin-4-ones as protein kinase inhibitors.
AR108090A1 (en) LIQUID FORMULATIONS OF (S) -N- (5 - ((R) -2- (2,5-DIFLUOROPHENYL) -PIRROLIDIN-1-IL) -PIRAZOLO [1,5-A] PIRIMIDIN-3-IL) -3 -HYDROXIPIRROLIDINA-1-CARBOXAMIDA
JOP20180089A1 (en) ): methods of treating pediatric cancers